Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Pfizer withdraws sickle cell drug Oxbryta
Pfizer’s Sickle Cell Drug Candidates Not Hit by Oxbryta Pull
All data considered, the benefit of the therapy, Oxbryta, “no longer outweighs the risk,” Pfizer said in a statement Wednesday. The company, which also announced discontinuing clinical trials as it investigates the findings,
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle cell drugs, analysts say
Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed up trials of new experimental rivals, Wall Street analysts said.
Pfizer pulls sickle cell treatment Oxbryta off global markets
The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain crises and "fatal events."
12h
FDA alerts patients about Pfizer's Oxbryta withdrawal
The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...
GEN
1d
Pfizer Withdraws SCD Drug Oxbryta after EMA Discloses 16 Deaths in Trials
Sixteen patients dosed with
Pfizer
’s sickle cell disease drug
Oxbryta
® (voxelotor) in a pair of clinical trials have died ...
1d
Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets
The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...
21h
Pfizer’s Stock Faces Challenges as Oxbryta Recall Impacts Drug Pipeline and Financial Projections
Pfizer (PFE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback